Alexander Uhrig

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10008518/publications.pdf

Version: 2024-02-01

759233 794594 20 2,236 12 19 citations h-index g-index papers 24 24 24 5398 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Best practices of highly infectious decedent management: Consensus recommendations from an international expert workshop. Journal of Occupational and Environmental Hygiene, 2022, 19, 129-138.	1.0	2
2	A proteomic survival predictor for COVID-19 patients in intensive care., 2022, 1, e0000007.		28
3	Randomized Clinical Study of Temporary Transvenous Phrenic Nerve Stimulation in Difficult-to-Wean Patients. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1169-1178.	5.6	28
4	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell, 2022, 185, 493-512.e25.	28.9	122
5	Preparing for patients with high-consequence infectious diseases: Example of a high-level isolation unit. PLoS ONE, 2022, 17, e0264644.	2.5	1
6	Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study. Infection, 2022, 50, 1441-1452.	4.7	10
7	Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. Antibiotics, 2022, 11, 758.	3.7	2
8	Heterogeneous approach to nebulization of antimicrobial agents in mechanically ventilated adults in a German tertiary care hospital: a cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 419-421.	2.9	1
9	Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection, 2021, 49, 703-714.	4.7	27
10	CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. Infection, 2021, 49, 757-762.	4.7	47
11	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study. Clinical Microbiology and Infection, 2021, 27, 1520.e7-1520.e10.	6.0	13
12	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	6.2	125
13	SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell, 2021, 184, 6243-6261.e27.	28.9	277
14	Evaluation of PEEP and prone positioning in early COVID-19 ARDS. EClinicalMedicine, 2020, 28, 100579.	7.1	49
15	Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell, 2020, 182, 1419-1440.e23.	28.9	1,162
16	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). Infection, 2020, 48, 619-626.	4.7	79
17	CytoResc – "CytoSorb―Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 577.	1.6	24
18	Standard operating procedures for antibiotic therapy and the occurrence of acute kidney injury: a prospective, clinical, non-interventional, observational study. Critical Care, 2014, 18, R120.	5.8	10

ALEXANDER UHRIG

#	Article	IF	CITATIONS
19	Influenza A (H1N1) vs non-H1N1 ARDS: Analysis of clinical course. Journal of Critical Care, 2014, 29, 340-346.	2.2	42
20	Avoiding invasive mechanical ventilation by extracorporeal carbon dioxide removal in patients failing noninvasive ventilation. Intensive Care Medicine, 2012, 38, 1632-1639.	8.2	172